Pharma BD Deal Intelligence

Novartis AG / SciNeuro Pharmaceuticals

2026 · Licensing/Option · $1.7B · Complete

SciNeuro Pharmaceuticals and Novartis Pharma entered a worldwide licensing and collaboration agreement to advance SciNeuro's de novo amyloid beta-targeted antibody program for Alzheimer's disease. The candidates incorporate SciNeuro's proprietary blood-brain barrier shuttle technology. The companies collaborate during early development, after which Novartis leads worldwide development and commercialization. SciNeuro receives USD 165M upfront plus research funding and is eligible for up to USD 1.5B in milestones plus tiered royalties.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2026 deals  ·  Novartis AG deals